On March 31, Lindsay Bealor Greenleaf, ADVI’s senior vice president and head of market access policy strategy (MAPS), was featured in Pharmaceutical Executive‘s article, “How Will MFN’s Effects on Medicare Impact Innovation?”

In the article, Lindsay shares insight on the current state of Most Favored Nation (MFN), it’s role within TrumpRx, and how these changes will impact Medicare patients.

Read more of Lindsay’s insights in Pharmaceutical Executive.